TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.

Nathan H Fowler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.